Arunava Chakravartty
Associate Vice President of Biostatistics Eli Lilly & Co.
Arunava is Associate Vice President of Biostatistics at Eli Lilly and Company, bringing nearly two decades of experience applying statistical innovation across oncology drug development. Previously, he spent over 12 years at Novartis, where he led global biostatistics teams supporting breast, gastrointestinal, and radio-sensitive cancer programs, advancing biomarker strategies, innovative trial designs, and quantitative decision-making from early development through registration. His expertise spans oncology, clinical pharmacology, precision medicine, and the integration of advanced statistical methodologies to improve development efficiency and patient outcomes.
Seminars
Thursday 19th November 2026
Using MIDD to Bridge Indications & Optimise Dose Selection
8:30 am
- Leveraging clinical pharmacology and quantitative modelling to translate evidence across therapeutic areas when applying established mechanisms to new patient populations
- Building models that account for differences in disease biology, treatment goals, and benefit-risk expectations across oncology and autoimmune indications
- Using MIDD to support first-in-indication dose selection when clinical data are available in one disease area but limited in another
- Understanding how therapeutic windows, safety tolerability, and dosing regimens must evolve when moving from oncology to chronic disease populations
